You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
Guidelines & Advice
About Guidelines Email Guidelines Team

Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma

ID: GL 11-11 Jul 2012
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
A. Gupta, X. Yao, S. Verma, H. Mackay, L. Hopkins, Sarcoma Disease Site Group, Gynecology Cancer Disease Site Group

Patient Population

Women with inoperable, locally advanced, recurrent, or metastatic uterine LMS.

Intended Guideline Users

Medical oncologists, gynecologic oncologists, general surgeons, radiation oncologists, pharmacists, and other clinicans who take care of the above target patients.

Research Question(s)

  1. Does chemotherapy (i.e., gemcitabine, gemcitabine plus docetaxel, doxorubicin, or trabectedin) improve clinical outcomes (i.e., tumour response rate, progression-free survival [PFS], overall survival [OS], toxicity, or quality of life [QOL]) in women with inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma (LMS)?
  2. Is there a difference in tumour response rate to chemotherapy (i.e., gemcitabine, gemcitabine plus docetaxel, doxorubicin, or trabectedin) between recurrent pelvic disease compared with extra-pelvic metastases in patients with uterine LMS?
pdf download Full Report (PDF) (578.72 KB)